Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

433
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
433
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

13
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
13
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

189
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
189
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.7K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

21
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
21
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

311
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
311

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Change in Hematoma Size after Dexamethasone Therapy in Chronic Subdural Hematoma Subtypes: A Prospective Study in Symptomatic Patients.

Journal of neurotrauma·2022
Same author

Reference intervals of urinary kidney injury biomarkers for middle-aged men and women determined by quantitative protein mass spectrometry.

Annals of clinical biochemistry·2022
Same author

Opioid prescribing patterns after arthroplasty of the knee and hip: a Dutch nationwide cohort study from 2013 to 2018.

Acta orthopaedica·2022
Same author

Valid Evidence for Diagnosis and Treatment of Infections in the Intensive Care Unit: Beyond Randomized Control Trial Study Design (Trial Emulation and Machine Learning).

Journal of clinical medicine·2022
Same author

Association between prescription opioid use and unplanned intensive care unit admission and mortality in the adult population of the Netherlands: a registry study.

British journal of anaesthesia·2022
Same author

External validation of risk scores to predict in-hospital mortality in patients hospitalized due to coronavirus disease 2019.

European journal of internal medicine·2022

Related Experiment Video

Updated: Aug 30, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.9K

[Current and future therapeutic options for COVID-19].

Marloes Dankers1,2, H Marjorie J M G Nelissen-Vrancken1, Marjolein Y Berger3

  • 1Instituut Verantwoord Medicijngebruik, Utrecht.

Nederlands Tijdschrift Voor Geneeskunde
|August 29, 2022
PubMed
Summary

Various anti-inflammatory and antiviral medications show efficacy in treating early and late COVID-19. Some therapies are effective against specific variants, while new treatments are emerging for early-stage disease.

More Related Videos

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.3K
Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.3K

Related Experiment Videos

Last Updated: Aug 30, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.9K
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.3K
Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.3K

Area of Science:

  • Pharmacology and Therapeutics
  • Infectious Diseases
  • Immunology

Background:

  • COVID-19 treatment has evolved, with a focus on managing inflammation and viral replication.
  • Different stages of COVID-19 (early vs. late) require distinct therapeutic approaches.
  • Emergence of SARS-CoV-2 variants necessitates ongoing evaluation of treatment efficacy.

Purpose of the Study:

  • To review and summarize current and emerging therapeutic agents for COVID-19.
  • To differentiate treatment strategies for early versus late-stage COVID-19.
  • To assess the effectiveness of various drug classes, including anti-inflammatories and antivirals.

Main Methods:

  • Literature review and synthesis of existing clinical data on COVID-19 treatments.
  • Categorization of therapies based on mechanism of action (e.g., anti-inflammatory, virus-inhibitor).
  • Evaluation of treatment efficacy in relation to disease stage and specific SARS-CoV-2 variants.

Main Results:

  • Dexamethasone, tocilizumab, and sarilumab are effective anti-inflammatory treatments for late COVID-19.
  • Anakinra, baricitinib, tofacitinib, and lenzilumab also show positive results in late COVID-19.
  • Budesonide is an off-label option for early COVID-19; remdesivir, molnupiravir, and nirmatrelvir/ritonavir reduce hospitalization risk in early disease.
  • Monoclonal antibodies have limited efficacy against the Omicron variant.
  • Fluvoxamine, l-arginine, AT-527, and ensovibep show promise for early COVID-19 treatment.

Conclusions:

  • A range of anti-inflammatory and antiviral agents are available for COVID-19 management.
  • Treatment selection depends on the stage of the disease and the specific SARS-CoV-2 variant.
  • Ongoing research is identifying promising new therapies for early COVID-19.